FSB Premier Wealth Management Inc. Buys 551 Shares of IQVIA Holdings Inc. (NYSE:IQV)

FSB Premier Wealth Management Inc. increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 20.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 3,285 shares of the medical research company’s stock after acquiring an additional 551 shares during the period. FSB Premier Wealth Management Inc.’s holdings in IQVIA were worth $646,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Wellington Management Group LLP lifted its holdings in shares of IQVIA by 12.7% in the 4th quarter. Wellington Management Group LLP now owns 9,791 shares of the medical research company’s stock worth $1,924,000 after acquiring an additional 1,106 shares during the last quarter. Schroder Investment Management Group lifted its stake in IQVIA by 4.5% in the fourth quarter. Schroder Investment Management Group now owns 77,715 shares of the medical research company’s stock worth $15,272,000 after purchasing an additional 3,333 shares during the last quarter. Allianz SE purchased a new position in shares of IQVIA during the fourth quarter valued at approximately $213,000. Allstate Corp bought a new position in shares of IQVIA during the fourth quarter valued at approximately $1,065,000. Finally, Brown Brothers Harriman & Co. lifted its stake in shares of IQVIA by 468.3% during the 4th quarter. Brown Brothers Harriman & Co. now owns 466 shares of the medical research company’s stock worth $92,000 after acquiring an additional 384 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 1.2 %

IQVIA stock opened at $177.27 on Monday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market cap of $31.25 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The stock has a 50-day moving average of $193.15 and a two-hundred day moving average of $206.05. IQVIA Holdings Inc. has a one year low of $176.03 and a one year high of $253.84.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Stephens began coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Bank of America lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Finally, William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.